Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 683 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT annonce que NASHnext® de Labcorp, basé sur sa technologie diagnostique non invasive NIS4® pour l’identification de la MASH à risque, est lancé via la plateforme « Labcorp OnDemand »
Regulatory Filings Classification · 92% confidence The document is a corporate press release announcing the launch of Genfit’s NASHnext® diagnostic test on Labcorp OnDemand. It contains marketing and product information, forward-looking statements, and contact details. It does not contain financial statements, voting results, management changes, or formal meeting materials. It is not an Annual Report, earnings release, or investor presentation. Therefore it falls under the general “Regulatory Filings” fallback category (RNS).
2026-06-08 French
GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH
Regulatory Filings Classification · 90% confidence The document is a corporate press release announcing the launch of a diagnostic test (NASHnext® powered by NIS4®) via Labcorp’s OnDemand platform. It does not present financial results, management discussion, board changes, capital markets transactions, regulatory forms, or other specific report types. It is a standalone corporate announcement that does not fit into the other defined categories, making it a general regulatory announcement. Under the classification scheme, such miscellaneous press releases are classified as Regulatory Filings (RNS).
2026-06-08 English
GENFIT : Forte présence scientifique et stratégique au Congrès EASL 2026
Regulatory Filings Classification · 90% confidence The document is a press release (“communiqué de presse”) announcing GENFIT’s scientific presence and abstracts at the EASL 2026 congress. It contains no financial statements, no voting or AGM material, no management changes, no debt or financing updates, and no detailed investor slide deck. It is a corporate announcement of operational/scientific activities and therefore falls into the miscellaneous regulatory announcement category.
2026-05-25 French
GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026
Regulatory Filings Classification · 12% confidence The document is a corporate press release highlighting GENFIT’s participation at a scientific congress, detailing poster presentations, events, and forward-looking statements. It does not present financial results (so it is not an Earnings Release or Annual/Interim Report), does not announce management or board changes, capital actions, dividends, share transactions, M&A activity, or other specific regulatory actions. It is not a formal investor presentation, call transcript or proxy material. Therefore, it falls into the fallback category for miscellaneous general announcements that do not fit any other specific category: Regulatory Filings (RNS).
2026-05-25 English
GENFIT : Information financière du premier trimestre 2026 et point sur les activités de la Société
Earnings Release Classification · 95% confidence The document is a press release (communiqué de presse) announcing Genfit’s first quarter 2026 financial results (cash position, revenue for Q1) along with a business activity update. It does not contain full financial statements but provides key highlights of the quarter’s performance. This matches the definition of an Earnings Release (ER). Q1 2026
2026-05-21 French
GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
Earnings Release Classification · 92% confidence The document is a press release titled “GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update,” summarizing key Q1 financial metrics (cash position, revenues) and corporate/program highlights. It does not include full financial statements or detailed analysis, but provides headline figures and business updates typical of an initial quarterly earnings announcement. This matches the definition of an Earnings Release (ER). Q1 2026
2026-05-21 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.